Status:
TERMINATED
The Effects of Dexmedetomidine and Remifentanil on Carotid Patients
Lead Sponsor:
The Cleveland Clinic
Conditions:
Carotid Artery Stenosis
Eligibility:
All Genders
50-80 years
Phase:
PHASE4
Brief Summary
We propose to test whether intraoperative administration of dexmedetomidine will reduce hemodynamic control in the intra- and post-operative periods and reduces PACU analgesic requirements in patients...
Detailed Description
Remifentanil is an amidopiperidine derivative with unique pharmacokinetic properties. Its steady-state volume of distribution is 30 L (3). Its context-sensitive half life is consistently short (3.2 mi...
Eligibility Criteria
Inclusion
- Consenting adult patients (age \>50 years) undergoing carotid endarterectomy with general anesthesia.
Exclusion
- Receiving another alpha 2-adrenoreceptor agonist;
- Contraindication to dexmedetomidine, including allergy;
- Current hepatic disease (liver function tests \> twice upper limit of normal);
- Renal insufficiency, as defined by a creatinine \> 2.0 mg/dL;
- Mentally impairment, including dementia or delirium;
- Heart block ;
- Sick sinus syndrome;
- Atrial fibrillation with a low ventricular response (\< 50 bpm);
- Absolute or relative hypovolemia;
- Prior stroke;
- Severe left-ventricular dysfunction
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
142 Patients enrolled
Trial Details
Trial ID
NCT00335972
Start Date
June 1 2006
End Date
May 1 2008
Last Update
August 11 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic
Cleveland, Ohio, United States, 44195